Traditional Persian medicine has introduced effective remedies in opioid dependence care. One of the most widely used remedies is an herbal formulation containing L. and L. (HF). This study investigated the effects of HF to attenuate the withdrawal signs and rewarding effects in morphine-dependent rats. Forty-nine male Wistar rats were randomly divided into seven groups. The control and vehicle groups received normal saline and sodium carboxymethyl cellulose, respectively. The morphine group received morphine for one week. The single and daily dose of HF groups received morphine similar to the morphine group, and HF (1.4 and 2.8 g/kg) once a day in the daily dose group and only on the last day of the experiment in the single dose of HF group. Finally, the withdrawal signs as well biochemical tests were evaluated. The behavioral parameters were assessed by conditioned place preference (CPP), elevated plus-maze and Y-maze tests. The antioxidant activity of HF was evaluated by measurement of serum contents of malondialdehyde, stable nitric oxide metabolites and total antioxidant capacity (TAC). Moreover, the protein expression of c-fos was assessed by western blotting. Daily treatment with HF significantly reduced the score of CPP behavioral test, all of the withdrawal signs, TAC and the c-fos protein level. The results indicated that HF might be a promising complementary treatment in reducing morphine-induced physical and psychological dependence probably through modulation of c-fos protein expression.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2022.2130293DOI Listing

Publication Analysis

Top Keywords

withdrawal signs
12
herbal formulation
8
groups received
8
morphine group
8
received morphine
8
daily dose
8
dose group
8
protein expression
8
c-fos protein
8
morphine
5

Similar Publications

Background: There are many barriers to prescribing medications for opioid use disorder (MOUD). This study evaluates the prevalence, patterns, and predictors of inpatient MOUD prescribing at discharge to patients with a diagnosis of opioid use/opioid use disorder (OUD) that developed opioid withdrawal during their hospital stay.

Methods: This multicenter, retrospective cross-sectional study occurred at three hospitals in Arizona.

View Article and Find Full Text PDF

Objective: Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC cessation remain ill-defined. We characterised clinical predictors and their combined effect on flares in patients with SLE who discontinued GC.

View Article and Find Full Text PDF
Article Synopsis
  • Fall risk and cognitive impairment are common issues in Parkinson's disease, necessitating effective treatments.
  • The study evaluated the safety and efficacy of TAK-071, a targeted medication, in individuals with Parkinson's who also experience these challenges.
  • Despite not showing significant improvement in gait variability, TAK-071 was found to enhance cognitive function, marking a potential positive outcome for patients.
View Article and Find Full Text PDF

The preclinical evaluation of drug-induced cardiotoxicity is critical for developing novel drug, helping to avoid drug wastage and post-marketing withdrawal. Although human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and the engineered heart organoid have been used for drug screening and mimicking disease models, they are always limited by the immaturity and lack of functionality of the cardiomyocytes. In this study, we constructed a Cardiomyocytes-on-a-Chip (CoC) that combines micro-grooves (MGs) and circulating mechanical stimulation to recapitulate the well-organized structure and stable beating of myocardial tissue.

View Article and Find Full Text PDF

Laboratory changes during dupilumab treatment for atopic dermatitis.

Actas Dermosifiliogr

January 2025

Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.

The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!